ReviewNutrients2021
Treatment-Related Dysgeusia in Oral and Oropharyngeal Cancer: A Comprehensive Review.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Development of depression in patients with oropharyngeal cancer: a systematic review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2026Pooled it
- Upper Airway Sensory Testing in Dysphagia - Implications for Clinical Practice and Future Research Directions.Dysphagia · 2025Pooled it
- Effect of a Novel Food Rich in Miraculin on the Intestinal Microbiome of Malnourished Patients with Cancer and Dysgeusia.Nutrients · 2025Trial
- Network-derived symptom architecture and simulated leverage points during radiotherapy for oral cancer.Asia-Pacific journal of oncology nursing · 2026Article
- Knowledge, Attitudes, and Practice of Clinicians Regarding Dysgeusia as a Complication of (Chemo) Radiotherapy.Acta stomatologica Croatica · 2026Article
- Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Dynamic changes in symptom clusters and their influencing factors in oral cancer patients throughout the treatment cycle: a longitudinal study based on principal component analysis and linear mixed-effects modeling.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Oral dryness related symptoms in radiation-treated head and neck cancer patients: a pilot study of oral microbiome composition and function.BMC microbiology · 2026Article
- Taste disorders in cancer patients and current therapeutic approaches: a narrative review of an understudied topic in supportive care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Nutritional Outcomes in HPV-Associated Oropharyngeal Squamous Cell Carcinoma After Transoral Robotic Surgery.The Laryngoscope · 2025Article
- Buccodental Toxicities Induced by Tyrosine Kinase Inhibitors in Patients Diagnosed with Renal Cell Carcinoma-A Literature Review.Dentistry journal · 2025Review
- Taste alterations in patients with cancer: an overview and recommendations for future research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Taste Dysfunction in Head and Neck Cancer: Pathophysiology and Clinical Management-A Comprehensive Review.Biomedicines · 2025Review
- Core preoperative symptoms and patients' symptom experiences in oral cancer: a mixed-methods study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- How do patients with head and neck cancer and low skeletal muscle mass experience cisplatin-based chemoradiotherapy? A qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Gustatory interface for operative assessment and taste decoding in patients with tongue cancer.Nature communications · 2024Article
- Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia.Cancers · 2024Article
- Carrier-Free Hybrid Nanoparticles for Enhanced Photodynamic Therapy in Oral Carcinoma via Reversal of Hypoxia and Oxidative Resistance.Pharmaceutics · 2024Article
- Treatment Complications of Head and Neck Cancers and Rehabilitation Measures: A Narrative Review.Cureus · 2024Review
- Vision Transformer-Based Multilabel Survival Prediction for Oropharynx Cancer After Radiation Therapy.International journal of radiation oncology, biology, physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cancer is the most common tumor of the head and neck region. Its management is based on surgical and systemic therapies. Taste disorders represent the most common side effect of these treatments; indeed, dysgeusia is noted by 70% of oral cancer patients. Despite survival remaining the primary endpoint of cancer patients, taste impairments can cause psychological distress. This comprehensive review describes the last decade's knowledge from the literature regarding taste alterations in patients with oral and oropharyngeal squamous cell carcinoma. A total of 26 articles in English, including prospective, cross-sectional, and case-control studies, and clinical trials were evaluated. Literature analysis shows that anti-cancer treatments can destroy taste cells, decrease and alter their receptors, and interrupt nerve transmission. Furthermore, the tumour itself can destroy the oral mucosal lining, which encloses the taste buds. Dysgeusia typically occurs in 3-4 weeks of treatments, and usually taste sensation is recovered within 3-12 months. However, some patients exhibit incomplete or no recovery, even several years later. Thus, dysgeusia can become a chronic issue and negatively influence patients' quality of life, worsening their dysphagia and their nutritional status. Physicians should be focused on preventing oncological treatment-related symptoms, offering the most suitable personalized support during therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.